Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Multi-center, Open-label, Parallel-group Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Sulthiame (S-054502) in Participants With Varying Degrees of Renal Impairment and Matched Healthy Control Participants With Normal Renal Function

NCT07857837 is registered in ClinicalTrials.gov with Shionogi as lead sponsor.

NCT NCT07857837
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07857837 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Multi-center, Open-label, Parallel-group Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Sulthiame (S-054502) in Participants With Varying Degrees of Renal Impairment and Matched Healthy Control Participants With Normal Renal Function
Lead sponsor
Shionogi
Phase
Phase 1
Overall status
Not yet recruiting
Start date
September 29, 2026
Completion date
December 11, 2026
Enrollment
30 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

renal impairment